BioSpace News Archive

Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the second quarter ended June 30, 2023.

ImmPrev Bio, Inc. has received an exclusive license from the University of Alabama at Birmingham (UAB) for the underlying patent to commercialize a novel diagnostic tool and early-stage treatment for Crohn’s disease, a type of inflammatory bowel disease.

Inimmune Corporation (“Inimmune”) today announced that the first subject has been dosed in Inimmune’s phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune’s TLR4 agonist product candidate under development as a potential treatment of allergic rhinitis.

Austrianova and ProAgni announced today the signing of a licensing and manufacturing agreement that foresees an intensification of joint activities between the two companies in the area of development and commercialization of shelf stable probiotic additives for cattle feed as well as for other farm animals.

The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research and Ferrer has been included by the World Health Organization in its List of Essential Medicines.

Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, announced that its high complexity CLIA laboratory has been awarded accreditation from the College of American Pathologists (CAP).

Alimera Sciences, Inc. announces that it will report second quarter financial results on August 10, 2023, prior to the market open.

ABM Therapeutics (ABM) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, a novel small molecule BRAF inhibitor developed by the company, for the treatment of patients with glioblastoma (GBM) bearing BRAF V600 mutation.

iRxReminder, LLC is thrilled to announce the enrollment of its first patients in the innovative NIMH-funded study, the TDtect™ Diagnostic.

Minerva Surgical, Inc. reported second quarter financial results for the period ended June 30, 2023.